Open-Label Study of Leuco-methylthioninium Bis(Hydromethanesulfonate) (LMTM) in Subjects With Alzheimer's Disease or Behavioral Variant Frontotemporal Dementia (bvFTD)

Summary

The purpose of this study is to provide subjects who have completed participation in a Phase 2 or Phase 3 trial of LMTM continued access to therapy and to evaluate the long-term safety of LMTM.

Timeline

Start

2014-08

Primary completion

2017-05

Completion

2017-05

Outcome

Outcome not reported

Stopped: “This study has been terminated for administrative reasons only.”

Drugs

Indications